A study of 100 hospitalized COVID19 patient urine samples has shown that Rametrix® Molecular Urinalysis can be an effective tool in detecting kidney problems associated with infection. Early detection of COVID19 complications will allow healthcare providers to more effectively intervene with enhanced patient care.
Development of Controlled Substance Scanner
The ProofMed-CS V1.0 Scanner is in the final phase of engineering laboratory validation and certification. Once this is completed (February, 2023) user testing with key hospital pharmacy partners will begin. This use of this analytical device will enable real-time and point-of-care detection of unauthorized diversion of controlled substances in busy...
Advisory Board Testimonials
Rametrix® Technologies is pleased to announce the formation of their Business and Medical Advisory Board. See what some of our members are saying: Mike Abbott (January, 2023): “The application of technology to the improvement of the human condition is a remarkable and worthwhile endeavor and Rametrix® is poised to leave its...